Investigacion

Juan Carlos Hernández Boluda

Juan Carlos Hernández Boluda
Juan Carlos Hernández Boluda
hernandez_jca@gva.es

Juan Carlos Hernández Boluda

Licenciado en Medicina en 1994 por la Universidad de Valencia. Realización de la residencia de Hematología en el Hospital Clínic de Barcelona (1995-1998). Lectura de la tesis doctoral titulada “Papel de los genes p16 y survivina en la progresión de la leucemia mieloide crónica a la crisis blástica”, Universidad de Barcelona, Junio 2005. Desde 2001 trabaja en el Servicio de Hematología y Oncología Médica del Hospital Clínico de Valencia. Ha publicado más de 60 trabajos en revistas científicas con factor de impacto, fundamentalmente en el campo del diagnóstico y tratamiento de las neoplasias mieloproliferativas crónicas.

 

La investigación se centra en los mecanismos implicados en la  progresión de las neoplasias mieloproliferativas crónicas de la fase  crónica a la fase leucémica.

Our research is focused on the molecular mechanisms involved in the  progression of the chronic myeloproliferative neoplasms from the  chronic phase to the leukemic phase.

Número total de publicaciones: 44. Factor de Impacto acumulado: 201.53
Epstein-Barr virus DNA load kinetics analysis in allogeneic hematopoietic stem cell transplant recipients: Is it of any clinical usefulness?
Solano C1, Mateo EM2, Pérez A3, Talaya A4, Terol MJ3, Albert E2, Giménez E2, Vinuesa V2, Piñana JL3, Boluda JCH3, Navarro D5
Journal of clinical virology. 2017 Oct. 26-32. FI: 3.051
Epidemiologic and Clinical Characteristics of Coronavirus and Bocavirus Respiratory Infections after Allogeneic Stem Cell Transplantation: A Prospective Single-Center Study
Piñana JL Madrid S, Pérez A, Hernández-Boluda JC, Giménez E, Terol MJ, Calabuig M, Navarro D, Solano C
Biology of blood and marrow transplantation. 2017 Nov. . FI: 3.98
Clinical characteristics, prognosis and treatment of myelofibrosis patients with severe thrombocytopenia
Hernández-Boluda JC, Correa JG, Alvarez-Larrán A, Ferrer-Marín F, Raya JM, Martínez-López J, Velez P, Pérez-Encinas M, Estrada N, García-Gutiérrez V, Fox ML, Luño E, Kerguelen A, Cuevas B, Durán MA, Ramírez MJ, Gómez-Casares M, Mata-Vázquez MI, Regadera A, Pereira A, Cervantes F; Grupo Español de Enfermedades Mieloproliferativas Filadelfia Negativas (GEMFIN)
British journal of haematology. 2017 Apr. . FI: 5.67
Impact of genotype on leukaemic transformation in polycythaemia vera and essential thrombocythaemia
Alvarez-Larrán A1, Senín A1, Fernández-Rodríguez C2, Pereira A3, Arellano-Rodrigo E3, Gómez M4, Ferrer-Marin F5, Martínez-López J6, Camacho L2, Colomer D7, Angona A1, Navarro B4, Cervantes F8, Besses C1, Bellosillo B2, Hernández-Boluda JC4.
British journal of haematology. 2017 Sep. 764-771. FI: 5.67
Impact of cytomegalovirus DNAemia on overall and non-relapse mortality in allogeneic stem cell transplant recipients.
Solano C, Giménez E, Piñana JL, Albert E, Vinuesa V, Hernández-Boluda JC, Amat P, Navarro D
Transplant infectious disease : an official journal of the Transplantation Society.. 2017 May 4. . FI: 1.459
A time-to-event model for acute kidney injury after reduced intensity conditioning stem cell transplantation using a tacrolimus and sirolimus-based graft-versus-host disease prophylaxis.
Piñana JL, Perez-Pitarch A, Garcia-Cadenas I, Barba P, Hernandez-Boluda JC, Esquirol A, Fox ML, Terol MJ, Queraltó JM, Vima J, Valcarcel D, Ferriols-Lisart R, Sierra J, Solano C, Martino R
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.. 2017 Apr 7. . FI: 3.98
A risk-adapted approach to treating respiratory syncytial virus and human parainfluenza virus in allogeneic stem cell transplantation recipients with oral ribavirin therapy: a pilot study.
Piñana JL, Hernández-Boluda JC, Calabuig M, Ballester I, Marín M, Madrid S, Teruel A, Terol MJ, Navarro D, Solano C
Transplant infectious disease : an official journal of the Transplantation Society.. 2017 May 19. . FI: 1.459
Autologous hematopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: comparison with secondary progressive multiple sclerosis.
Casanova B, Jarque I, Gascón F, Hernández-Boluda JC, Pérez-Miralles F, de la Rubia J, Alcalá C, Sanz J, Mallada J, Cervelló A, Navarré A, Carcelén-Gadea M, Boscá I, Gil-Perotin S, Solano C, Sanz MA, Coret F
Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology.. 2017 Apr 10. . FI: 1.783
A BCR-ABL1 cutoff of 1.5% at 3 months, determined by the GeneXpert system, predicts an optimal response in patients with chronic myeloid leukemia
García-Gutiérrez V, Gómez-Casares MT, Puerta JM, Alonso-Domínguez JM, Osorio S, Hernández-Boluda JC, Collado R, Ramírez MJ, Ibáñez F, Martín ML, Rodríguez-Gambarte JD, Martínez-Laperche C, Gómez M, Fiallo DV, Redondo S, Rodríguez A, Ruiz-Nuño C, Steegmann JL, Jiménez-Velasco A; Spanish Group of Chronic Myeloid Leukemia (GELMC)
Plos One. 2017 Mar 9. e0173532. FI: 2.806
The kinetics of torque teno virus plasma DNA load shortly after engraftment predicts the risk of high-level CMV DNAemia in allogeneic hematopoietic stem cell transplant recipients
Albert E, Solano C, Giménez E, Focosi D, Pérez A, Macera L, Piñana JL, Boluda JCH, Maggi F, Navarro D
Bone marrow transplantation. 2017 Oct. . FI: 3.874
Performance of the myelofibrosis secondary to PV and ET-prognostic model (MYSEC-PM) in a series of 262 patients from the Spanish registry of myelofibrosis
Hernández-Boluda JC, Pereira A, Correa JG, Alvarez-Larrán A, Ferrer-Marín F, Raya JM, Martínez-López J, Pérez-Encinas M, Estrada N, Velez P, Fox ML, García-Gutiérrez V, Payer A, Kerguelen A, Cuevas B, Durán MA, Ramírez MJ, Gómez-Casares MT, Mata-Vázquez MI, Mora E, Martínez-Valverde C, Gómez M, Cervantes F
Leukemia. 2017 Sep 22. . FI: 11.702
Predictive factors for anemia response to erythropoiesis-stimulating agents in myelofibrosis
Hernández-Boluda JC, Correa JG, García-Delgado R, Martínez-López J, Alvarez-Larrán A, Fox ML, García-Gutiérrez V, Pérez-Encinas M, Ferrer-Marín F, Mata-Vázquez MI, Raya JM, Estrada N, García S, Kerguelen A, Durán MA, Albors M, Cervantes F
European journal of haematology. 2017 Apr. 407-414. FI: 2.653
Primary prophylaxis of invasive fungal infections with posaconazole or itraconazole in patients with acute myeloid leukaemia or high-risk myelodysplastic syndromes undergoing intensive cytotoxic chemotherapy: A real-world comparison
Tormo M, Pérez-Martínez A, Calabuig M, Hernández-Boluda JC, Amat P, Navarro D, Solano C
Mycoses. 2017 Nov 10. . FI: 6.183
When should preemptive antiviral therapy for active CMV infection be withdrawn from allogeneic stem cell transplant recipients?
Solano C, Giménez E, Piñana JL, Hernández-Boluda JC, Amat P, Vinuesa V, Navarro D
Bone marrow transplantation.. 2017 Jun 5. . FI: 3.874
Lack of evidence for a reciprocal interaction between bacterial and cytomegalovirus infection in the allogeneic stem cell transplantation setting
Vinuesa V, Solano C, Giménez E, Piñana JL, Boluda JC, Amat P, Navarro D
Transplant international. 2016 Nov. 1196-1204. FI: 3.079
JAK2 inhibitors
Hernández Boluda JC, Gómez M, Pérez A
Medicina clínica. 2016 Jul 15. 70-5. FI: 1.267
High rate of recurrent venous thromboembolism in patients with myeloproliferative neoplasms and effect of prophylaxis with vitamin K antagonists
De Stefano V, Ruggeri M, Cervantes F, Alvarez-Larrán A, Iurlo A, Randi ML, Elli E, Finazzi MC, Finazzi G, Zetterberg E, Vianelli N, Gaidano G, Rossi E, Betti S, Nichele I, Cattaneo D, Palova M, Ellis MH, Cacciola R, Tieghi A, Hernandez-Boluda JC, Pungolino E, Specchia G, Rapezzi D, Forcina A, Musolino C, Carobbio A, Griesshammer M, Sant'Antonio E, Vannucchi AM, Barbui T
Leukemia. 2016 Oct. 2032-2038. FI: 11.702
GvHD prophylaxis with tacrolimus plus sirolimus after reduced intensity conditioning allogeneic transplantation: results of a multicenter study
Parody R, López-Corral L, Lopez-Godino O, Martinez C, Martino R, Solano C, Barba P, Caballero D, García-Cadenas I, Piñana JL, Marquez-Malaver FJ, Vazquez L, Esquirol A, Boluda JC, Sanchez-Guijo F, Pérez-Simon JA
Bone marrow transplantation. 2016 Nov. 1524-1526. FI: 3.874
Successful treatment of hepatitis C virus infection with sofosbuvir and simeprevir in the early phase of an allogeneic stem cell transplant.
Piñana JL, Serra MÁ, Hernández-Boluda JC, Navarro D, Calabuig M, Solano C
Transplant infectious disease : an official journal of the Transplantation Society.. 2016 Feb. 89-92. FI: 2.064
Risk factors for non-melanoma skin cancer in patients with essential thrombocythemia and polycythemia vera.
Gómez M, Guillem V, Pereira A, Ferrer-Marín F, Álvarez-Larrán A, Kerguelen A, Estrada N, Martínez-López J, Angona A, Amat P, Navarro B, Besses C, Hernández-Boluda JC
European journal of haematology. 2016 Mar. 285-90. FI: 2.653
Risk of thrombosis according to need of phlebotomies in patients with polycythemia vera treated with hydroxyurea.
Alvarez-Larrán A, Pérez-Encinas M, Ferrer-Marin F, Hernández-Boluda JC, Ramírez MJ, Martínez-López J, Magro E, Cruz Y, Mata MI, Aragües P, Fox ML, Cuevas B, Montesdeoca S, Hernández-Rivas JA, García-Gutiérrez V, Gómez-Casares MT, Steegmann JL, Durán MA, Gómez M, Kerguelen A, Bárez A, García MC, Boqué C, Raya JM, Martinez C, Albors M, Garcia F, Burgaleta C, Besses C
Haematologica. 2016 Sep 29. . FI: 7.702
Alleviating anemia and thrombocytopenia in myelofibrosis patients
Cervantes F, Correa JG, Hernandez-Boluda JC
Expert review of hematology. 2016 May. 489-96. FI: 2.246
Splanchnic vein thrombosis in myeloproliferative neoplasms: risk factors for recurrences in a cohort of 181 patients
De Stefano V, Vannucchi AM, Ruggeri M, Cervantes F, Alvarez-Larrán A, Iurlo A, Randi ML, Pieri L, Rossi E, Guglielmelli P, Betti S, Elli E, Finazzi MC, Finazzi G, Zetterberg E, Vianelli N, Gaidano G, Nichele I, Cattaneo D, Palova M, Ellis MH, Cacciola E, Tieghi A, Hernandez-Boluda JC, Pungolino E, Specchia G, Rapezzi D, Forcina A, Musolino C, Carobbio A, Griesshammer M, Barbui T
Blood cancer journal. 2016 Nov. e493. FI: 6.126
Antiplatelet therapy versus observation in low-risk essential thrombocythemia with CALR mutation.
Alvarez-Larrán A, Pereira A, Guglielmelli P, Hernández-Boluda JC, Arellano-Rodrigo E, Ferrer-Marín F, Samah A, Griesshammer M, Kerguelen A, Andreasson B, Burgaleta C, Schwarz J, García-Gutiérrez V, Ayala R, Barba P, Gómez-Casares MT, Paoli C, Drexler B, Zweegman S, McMullin MF, Samuelsson J, Harrison C, Cervantes F, Vannucchi AM, Besses C
Haematologica. 2016 May 12. . FI: 7.702
Current opinion and consensus statement regarding the diagnosis, prognosis, and treatment of patients with essential thrombocythemia: a survey of the Spanish Group of Ph-negative Myeloproliferative Neoplasms (GEMFIN) using the Delphi method.
Besses C, Hernández-Boluda JC, Pérez Encinas M, Raya JM, Hernández-Rivas JM, Jiménez Velasco A, Martínez Lopez J, Vicente V, Burgaleta C, GEMFIN
Annals of hematology. 2016 Apr. 719-32. FI: 2.634
Frequency and prognostic value of resistance/intolerance to hydroxycarbamide in 890 patients with polycythaemia vera.
Alvarez-Larrán A, Kerguelen A, Hernández-Boluda JC, Pérez-Encinas M, Ferrer-Marín F, Bárez A, Martínez-López J, Cuevas B, Mata MI, García-Gutiérrez V, Aragües P, Montesdeoca S, Burgaleta C, Caballero G, Hernández-Rivas JA, Durán MA, Gómez-Casares MT, Besses C, Grupo Español de Enfermedades Mieloproliferativas Filadelfia Negativas (GEMFIN)
British journal of haematology. 2016 Mar. 786-93. FI: 5.67
Long-term results of prednisone treatment for the anemia of myelofibrosis.
Hernández-Boluda JC, Martínez-Trillos A, García-Gutiérrez V, Ferrer-Marín F, Xicoy B, Alvarez-Larrán A, Kerguelen A, Barba P, Gómez M, Herrera JC, Correa JG, Cervantes F
Leukemia & lymphoma. 2016 Jan. 120-4. FI: 2.891
Risk assessment for trombosis and survival in essential thrombocythemia
Hernández Boluda JC
Medicina clínica. 2015 Mar 15. 257-8. FI: 1.267
BCL2 gene polymorphisms and splicing variants in chronic myeloid leukemia.
Guillem V, Amat P, Collado M, Cervantes F, Alvarez-Larrán A, Martínez J, Tormo E, Eroles P, Solano C, Hernández-Boluda JC
Leukemia Research. 2015 Aug 28. . FI: 2.606
Danazol therapy for the anemia of myelofibrosis: assessment of efficacy with current criteria of response and long-term results.
Cervantes F, Isola IM, Alvarez-Larrán A, Hernández-Boluda JC, Correa JG, Pereira A
Annals of hematology. 2015 Nov. 1791-6. FI: 2.634
Oral anticoagulation to prevent thrombosis recurrence in polycythemia vera and essential thrombocythemia.
Hernández-Boluda JC, Arellano-Rodrigo E, Cervantes F, Alvarez-Larrán A, Gómez M, Barba P, Mata MI, González-Porras JR, Ferrer-Marín F, García-Gutiérrez V, Magro E, Moreno M, Kerguelen A, Pérez-Encinas M, Estrada N, Ayala R, Besses C, Pereira A, Grupo Español de Enfermedades Mieloproliferativas Filadelfia Negativas (GEMFIN)
Annals of hematology. 2015 Jun. 911-8. FI: 2.634
Target hematologic values in the management of essential thrombocythemia and polycythemia vera.
Hernández-Boluda JC, Gómez M
European journal of haematology. 2015 Jan. 42678. FI: 2.066
The International Prognostic Scoring System does not accurately discriminate different risk categories in patients with post-essential thrombocythemia and post-polycythemia vera myelofibrosis.
Hernández-Boluda JC, Pereira A, Gómez M, Boqué C, Ferrer-Marín F, Raya JM, García-Gutiérrez V, Kerguelen A, Xicoy B, Barba P, Martínez J, Luño E, Alvarez-Larrán A, Martínez-López J, Arbelo E, Besses C, Grupo Español de Enfermedades Mieloproliferativas Filadelfia Negativas (GEMFIN)
Haematologica. 2014 Apr. e55-7. FI: 5.868
Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea.
Alvarez-Larrán A, Martínez-Avilés L, Hernández-Boluda JC, Ferrer-Marín F, Antelo ML, Burgaleta C, Mata MI, Xicoy B, Martínez-Trillos A, Gómez-Casares MT, Durán MA, Marcote B, Ancochea A, Senín A, Angona A, Gómez M, Vicente V, Cervantes F, Bellosillo B, Besses C
Annals of hematology. 2014 Dec. 2037-43. FI: 2.396
BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia.
Zabriskie MS, Eide CA, Tantravahi SK, Vellore NA, Estrada J, Nicolini FE, Khoury HJ, Larson RA, Konopleva M, Cortes JE, Kantarjian H, Jabbour EJ, Kornblau SM, Lipton JH, Rea D, Stenke L, Barbany G, Lange T, Hernández-Boluda JC, Ossenkoppele GJ, Press RD, Chuah C, Goldberg SL, Wetzler M, Mahon FX, Etienne G, Baccarani M, Soverini S, Rosti G, Rousselot P, Friedman R, Deininger M, Reynolds KR, Heaton WL, Eiring AM, Pomicter AD, Khorashad JS, Kelley TW, Baron R, Druker BJ, Deininger MW, O'Hare T
Cancer cell. 2014 Sep 8. 428-42. FI: 23.893
JAK2V617F monitoring in polycythemia vera and essential thrombocythemia: Clinical usefulness for predicting myelofibrotic transformation and thrombotic events.
Alvarez-Larrán A, Bellosillo B, Pereira A, Kerguelen A, Carlos Hernández-Boluda J, Martínez-Avilés L, Fernández-Rodríguez C, Gómez M, Lombardía L, Angona A, Ancochea A, Senín A, Longarón R, Navarro B, Collado M, Besses C
American journal of hematology. 2014 May. 517-23. FI: 3.798
A polymorphism in the TYMP gene is associated with the outcome of HLA-identical sibling allogeneic stem cell transplantation.
Guillem V, Hernández-Boluda JC, Gallardo D, Buño I, Bosch A, Martínez-Laperche C, de la Cámara R, Brunet S, Martin C, Nieto JB, Martínez C, Pérez A, Montoro J, Garcia-Noblejas A, Solano C, Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group (GETH)
American journal of hematology. 2013 Oct. 883-9. FI: 3.477
Cytoreduction plus low-dose aspirin versus cytoreduction alone as primary prophylaxis of thrombosis in patients with high-risk essential thrombocythaemia: an observational study.
Alvarez-Larrán A, Pereira A, Arellano-Rodrigo E, Hernández-Boluda JC, Cervantes F, Besses C
British journal of haematology. 2013 Jun. 865-71. FI: 4.942
Clinical evaluation of the European LeukemiaNet response criteria in patients with essential thrombocythemia treated with anagrelide.
Hernández-Boluda JC, Pereira A, Cervantes F, Gómez M, Arellano-Rodrigo E, Alvarez-Larrán A, Ferrer-Marín F, Kerguelen A, Márquez JA, Antelo ML, Besses C, Grupo Español de Enfermedades Mieloproliferativas Filadelfia Negativas (GEMFIN)
Annals of hematology. 2013 Jun. 771-5. FI: 2.866
A polymorphism in the XPD gene predisposes to leukemic transformation and new nonmyeloid malignancies in essential thrombocythemia and polycythemia vera.
Hernández-Boluda JC, Pereira A, Cervantes F, Alvarez-Larrán A, Collado M, Such E, Arilla MJ, Boqué C, Xicoy B, Maffioli M, Bellosillo B, Marugán I, Amat P, Besses C, Guillem V
Bmc medical research methodology. 2012 May 31. 5221-8. FI: 9.06
Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera.
Alvarez-Larrán A, Pereira A, Cervantes F, Arellano-Rodrigo E, Hernández-Boluda JC, Ferrer-Marín F, Angona A, Gómez M, Muiña B, Guillén H, Teruel A, Bellosillo B, Burgaleta C, Vicente V, Besses C
Blood. 2012 Feb 9. 1363-9. FI: 9.06
Absence of mutations in the activation loop and juxtamembrane domains of VEGFR-1 and VEGFR-2 gene in chronic myelomonocytic leukemia (CMML).
Such E, Cervera J, Ibáñez M, Gómez-Seguí I, Luna I, López-Pavía M, Mallo M, Collado R, Vicente A, Hernández-Boluda JC, Luño E, Andreu R, Sanz GF, Sanz MA
Mechanisms of ageing and development. 2012 Mar. e50-1. FI: 2.764
Functional polymorphisms in SOCS1 and PTPN22 genes correlate with the response to imatinib treatment in newly diagnosed chronic-phase chronic myeloid leukemia.
Guillem V, Amat P, Cervantes F, Alvarez-Larrán A, Cervera J, Maffioli M, Bellosillo B, Collado M, Marugán I, Martínez-Ruiz F, Hernández-Boluda JC
Leukemia research. 2012 Feb. 174-81. FI: 2.764
Polymyositis after donor lymphocyte infusion.
Montoro J, Hernández-Boluda JC, Arbona C, Solano C
International journal of hematology. 2012 Sep. 386-9. FI: 1.681

Role of the RUNX1/CBF-beta/p300/HIPK2 complex in the leukemic progression of the chronic myeloproliferative neoplasms.

Referencia:
PI13/00636
Investigador principal:
Juan Carlos Hernández Boluda
Entidad financiadora:
Instituto de Salud Carlos III
Duración:
01/01/2014 - 31/12/2016
Presupuesto total:
€79.860

Estudio de la predisposición genética individual a desarrollar leucemia aguda en los pacientes con síndromes mieloproliferativos crónicos Ph-negativos.

Referencia:
PS09/02324
Investigador principal:
Juan Carlos Hernández Boluda
Entidad financiadora:
Instituto de Salud Carlos III
Duración:
01/01/2010 - 31/12/2012
Presupuesto total:
€38.115